Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes.
CONCLUSIONS: Ticagrelor monotherapy after 1-month DAPT provided consistent treatment effects on ischemic endpoints in patients with or without ACS but only the former experienced a net clinical benefit. Trial registration ClinicalTrials.gov number NCT03231059.
PMID: 32482616 [PubMed - as supplied by publisher]
Source: EuroIntervention - Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
More News: Bleeding | Cardiology | Cardiovascular & Thoracic Surgery | Heart | Heart Attack | Heart Disease | Ischemic Stroke | Stroke | Study